Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality
other_biological
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05914389CT.gov Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Colon Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clostridium Butyricum (this asset) | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | CCC · 53 |
| Tranexamic Acid | Assaf-Harofeh Medical Center | P4 | BB |
| Fluorouracilum | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | BB |
| Oxaliplatin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P2 | B |
| Irinotecan | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Cetuximab | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P2 | B |
| Regorafenib | City of Hope Medical Center | P2 | B |
| Celecoxib | Tel-Aviv Sourasky Medical Center | P3 | B |
| Nivolumab | M.D. Anderson Cancer Center | P1/2 | B |
+26 more in the Malignant Colon Neoplasm cohort
Other indications for Clostridium Butyricum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | B · 62 |
| Colorectal Cancer | — | P4 | CCC · 54 |
| Rectal Carcinoma | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Tranexamic AcidAssaf-Harofeh Medical CenterBB
- FluorouracilumFondazione Policlinico Universitario Agostino Gemelli IRCCSBB
- OxaliplatinSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityB
- IrinotecanFondazione Policlinico Universitario Agostino Gemelli IRCCSB
- CetuximabFondazione Policlinico Universitario Agostino Gemelli IRCCSB
Citation
Floatz Terminal. Clostridium Butyricum in Malignant Colon Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/clostridium-butyricum-malignant-colon-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →